PL3740282T3 - Inhibitory metalotioneiny do leczenia cukrzycy, zapalenia wątroby i/lub zapalnej choroby wątroby - Google Patents
Inhibitory metalotioneiny do leczenia cukrzycy, zapalenia wątroby i/lub zapalnej choroby wątrobyInfo
- Publication number
- PL3740282T3 PL3740282T3 PL19703874.8T PL19703874T PL3740282T3 PL 3740282 T3 PL3740282 T3 PL 3740282T3 PL 19703874 T PL19703874 T PL 19703874T PL 3740282 T3 PL3740282 T3 PL 3740282T3
- Authority
- PL
- Poland
- Prior art keywords
- metallothionein
- hepatitis
- inhibitors
- liver disease
- treating diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 | |
| PCT/US2019/013934 WO2019143767A1 (en) | 2018-01-17 | 2019-01-17 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3740282T3 true PL3740282T3 (pl) | 2025-07-21 |
Family
ID=65324621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19703874.8T PL3740282T3 (pl) | 2018-01-17 | 2019-01-17 | Inhibitory metalotioneiny do leczenia cukrzycy, zapalenia wątroby i/lub zapalnej choroby wątroby |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (pl) |
| EP (2) | EP4596042A3 (pl) |
| JP (2) | JP7486423B2 (pl) |
| KR (2) | KR102937161B1 (pl) |
| CN (2) | CN120267797A (pl) |
| AU (2) | AU2019209491B2 (pl) |
| BR (1) | BR112020014346A2 (pl) |
| CA (1) | CA3088661A1 (pl) |
| EA (1) | EA202091533A1 (pl) |
| ES (1) | ES3033317T3 (pl) |
| HR (1) | HRP20250727T1 (pl) |
| HU (1) | HUE072418T2 (pl) |
| IL (2) | IL316486A (pl) |
| MX (1) | MX2020007384A (pl) |
| PH (1) | PH12020551076A1 (pl) |
| PL (1) | PL3740282T3 (pl) |
| RS (1) | RS66918B1 (pl) |
| SG (1) | SG11202006421RA (pl) |
| SM (1) | SMT202500233T1 (pl) |
| WO (1) | WO2019143767A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020186247A1 (en) | 2019-03-13 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| BR112022000705A2 (pt) | 2019-07-15 | 2022-03-22 | Univ Connecticut | Anticorpos de metalotioneína e seu uso |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
| WO2025226837A1 (en) * | 2024-04-24 | 2025-10-30 | University Of Connecticut | Anti-bacterial metallothionein antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) * | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| US8658174B2 (en) | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
| WO2011050052A2 (en) * | 2009-10-20 | 2011-04-28 | Georgia State University Research Foundation, Inc. | Protein agent for diabetes treatment and beta cell imaging |
| KR20130065728A (ko) | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| CA2840282C (en) * | 2011-07-08 | 2018-11-13 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| US20160215042A1 (en) * | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| EP3149049B1 (en) * | 2014-05-27 | 2022-10-26 | The University Of Queensland | Il-22 for use in treating metabolic disorders |
| US9487783B2 (en) * | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
-
2019
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
- 2019-01-17 KR KR1020207022117A patent/KR102937161B1/ko active Active
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 KR KR1020267006914A patent/KR20260042289A/ko active Pending
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US12583916B2/en active Active
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202500233T1 (it) | Inibitori della metallotioneina per il trattamento del diabete, dell'epatite e/o della malattia infiammatoria del fegato | |
| IL283268A (en) | Methods and devices for treating a disease with biotherapeutics | |
| IL285461A (en) | Processes and compounds | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| DK3880660T3 (da) | Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet | |
| DK4028010T3 (da) | Vs-6063 i kombination med ch5126766 til behandlingen af kræft | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| EP3784716A4 (en) | Curative | |
| KR102223657B9 (ko) | 염증성 장질환 예방 또는 치료용 약학적 조성물 | |
| DK3897672T5 (da) | Hbv kombinationsbehandling | |
| IL261738A (en) | Method and composition for treating inflammatory bowel disease | |
| IL268874A (en) | Peptides and methods for the treatment of diabetes | |
| ZA202205289B (en) | Compositions and methods for treating liver disease | |
| EP3833820C0 (en) | ENHANCED CHARGER CONTROLS | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| EP3609522A4 (en) | METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES | |
| GB201721287D0 (en) | Treatment for inflammatory disease | |
| LT4034122T (lt) | Hiperfenilalaninemijos gydymo būdai | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| PL3448409T3 (pl) | Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami | |
| IL286857A (en) | Methods for the treatment of beta-thalassemia | |
| DK3319616T3 (da) | Pektinsammensætninger til at forebygge og behandle inflammatoriske sygdomme | |
| HUE053924T2 (hu) | Kompozíció cukorbetegség kezelésére | |
| EP3705532A4 (en) | CURING COMPOSITION | |
| SE1750017A1 (sv) | Method and arrangement for metal hardening |